Trial
NCT02593929
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pittsburgh
Collaborators
—
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
ruxolitinib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-08